<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30482263</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>47</Issue><PubDate><Year>2018</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title><ISOAbbreviation>Euro Surveill</ISOAbbreviation></Journal><ArticleTitle>Acute flaccid paralysis (AFP) surveillance: challenges and opportunities from 18 years' experience, Spain, 1998 to 2015.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1700423</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2807/1560-7917.ES.2018.23.47.1700423</ELocationID><Abstract><AbstractText>Acute flaccid paralysis (AFP) surveillance is key for global polio eradication. It allows detecting poliovirus (PV) reintroductions from endemic countries. This study describes AFP surveillance in Spain from 1998 to 2015. During this time, 678 AFP cases were reported to the Spanish National Surveillance Network. The mean notification rate was 0.58 AFP cases/100,000 population under 15 years old (range: 0.45/100,000-0.78/100,000). Two periods (P) are described: P1 (1998-2006) with the AFP notification rate ranging from 0.66/100,000 to 0.78/100,000, peaking in 2001 (0.84/100,000); and P2 (2007-2015) when the AFP rate ranged from 0.43/100,000 to 0.57/100,000, with the lowest rate in 2009 (0.31/100,000). No poliomyelitis cases were caused by wild PV infections, although two Sabin-like PVs and one imported vaccine-derived PV-2 were detected. Overall, 23 (3.4%) cases met the hot case definition. Most cases were clinically diagnosed with Guillain-Barr&#xe9; syndrome (76.9%; 504/655). The adequate stool collection rate ranged from 33.3% (7/21) to 72.5% (29/40). The annual proportion of AFP cases with non-polio enterovirus findings varied widely across the study period. AFP surveillance with laboratory testing for non-polio enteroviruses must be maintained and enhanced both to monitor polio eradication and to establish sensitive surveillance for prompt detection of other enteroviruses causing serious symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masa-Calles</LastName><ForeName>Josefa</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torner</LastName><ForeName>Nuria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Agency of Catalonia, Generalitat of Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Perea</LastName><ForeName>Noem&#xed;</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres de Mier</LastName><ForeName>Mar&#xed;a de Viarce</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Mart&#xed;nez</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabrerizo</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Polio Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo-Garc&#xed;a</LastName><ForeName>Virtudes</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Servicio de Vigilancia y Salud Laboral, Consejer&#xed;a de Salud, Andaluc&#xed;a, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malo</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Vigilancia en Salud P&#xfa;blica, D.G. de Salud P&#xfa;blica, Departamento de Sanidad, Arag&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolles</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Vigilancia Epidemiol&#xf3;gica, Consejer&#xed;a de Sanidad, Instituto de Investigaci&#xf3;n Sanitaria del Principado de Asturias, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portell</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Vigilancia Epidemiol&#xf3;gica, Conselleria de Salut, Fam&#xed;lia i Bienestar Social Baleares, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abad&#xed;a</LastName><ForeName>Natividad</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiologia y Prevenci&#xf3;n, Direcci&#xf3;n General Salud P&#xfa;blica, Servicio Canario de Salud, Canarias, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>Aniceto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n de Vigilancia Epidemiol&#xf3;gica, D.G. de Salud P&#xfa;blica, Cantabria, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Hern&#xe1;ndez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, D.G. de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Castilla-La Mancha, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos</LastName><ForeName>Henar</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Servicio de Vigilancia Epidemiol&#xf3;gica y Enfermedades Transmisibles, D.G. de Salud P&#xfa;blica, Consejer&#xed;a de Sanidad, Castilla y Le&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabella</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Microbiology Department, Hospital de la Santa Creu i Sant Pau, Microbiology &amp; Genetics Department, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mar&#xed;n</LastName><ForeName>Celia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servei de Vigil&#xe0;ncia i Control Epidemiol&#xf2;gic, Conselleria de Sanitat Universal i Salut P&#xfa;blica, Comunitat Valenciana, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Subdirecci&#xf3;n de Epidemiolog&#xed;a. D.G. de Salud P&#xfa;blica, Servicio Extreme&#xf1;o de Salud, Consejer&#xed;a de Salud y Pol&#xed;ticas Sociales, Extremadura, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losada</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Servizo de Epidemiolox&#xed;a, Direcci&#xf3;n Xeral de Sa&#xfa;de P&#xfa;blica, Conseller&#xed;a de Sanidade, Xunta de Galicia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez</LastName><ForeName>Juan Garc&#xed;a</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, Subdirecci&#xf3;n General de Epidemiolog&#xed;a, Direcci&#xf3;n General de Salud P&#xfa;blica, Comunidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieto</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, Subdirecci&#xf3;n General de Epidemiolog&#xed;a, Direcci&#xf3;n General de Salud P&#xfa;blica, Comunidad Aut&#xf3;noma de Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ort&#xfa;zar</LastName><ForeName>Visitaci&#xf3;n Garc&#xed;a</ForeName><Initials>VG</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, D. G. de Salud P&#xfa;blica y Adicciones, Consejer&#xed;a de Salud, Regi&#xf3;n de Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cenoz</LastName><ForeName>Manuel Garc&#xed;a</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Spanish Consortium for Research in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a y Prevenci&#xf3;n Sanitaria, Instituto de Salud P&#xfa;blica de Navarra, IdiSNA, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arteagoitia</LastName><ForeName>Jos&#xe9; Mar&#xed;a</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Servicio de vigilancia epidemiol&#xf3;gica y vacunas, Direcci&#xf3;n de Salud P&#xfa;blica y Adicciones, Departamento de Salud, Pa&#xed;s Vasco, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>&#xc1;ngela Blanco</ForeName><Initials>&#xc1;B</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n de Vigilancia Epidemiol&#xf3;gica y Control de Enfermedades Transmisibles, D.G de Salud P&#xfa;blica y Consumo, Consejer&#xed;a de Salud, La Rioja, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivas</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, Consejer&#xed;a de Sanidad y Consumo, Ceuta, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castrillejo</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Epidemiolog&#xed;a, D.G. de Sanidad y Consumo, Consejer&#xed;a de Presidencia y Salud P&#xfa;blica, Melilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Spanish AFP Surveillance Working Group</CollectiveName><AffiliationInfo><Affiliation>The other members of the Spanish AFP Surveillance Working Group are listed at the end of this article.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Sweden</Country><MedlineTA>Euro Surveill</MedlineTA><NlmUniqueID>100887452</NlmUniqueID><ISSNLinking>1025-496X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018563" MajorTopicYN="N">Disease Notification</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="N">Poliovirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Spain</Keyword><Keyword MajorTopicYN="N">acute flaccid paralysis surveillance</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">poliomyelitis eradication</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword><Keyword MajorTopicYN="N">vaccine preventable disease</Keyword></KeywordList><CoiStatement><b>Conflict of interest:</b> None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30482263</ArticleId><ArticleId IdType="pmc">PMC6341937</ArticleId><ArticleId IdType="doi">10.2807/1560-7917.ES.2018.23.47.1700423</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). Acute flaccid paralysis (AFP) surveillance: the surveillance strategy for poliomyelitis eradication. Weekly Epidemiological Record. Geneva: WHO; 1998. Available from: http://www.who.int/docstore/wer/pdf/1998/wer7316.pdf</Citation></Reference><Reference><Citation>World Health Organization (WHO). WHO statement on the 8th IHR Emergency Committee meeting regarding the international spread of poliovirus. Geneva: WHO; 2016. [Accessed 10 Dec 2016]. Available from: http://www.who.int/mediacentre/news/statements/2016/8th-IHR-emergency-committee-polio/en/</Citation></Reference><Reference><Citation>World Health Organization (WHO). WHO statement on the meeting of the International Health Regulations Emergency Committee concerning the International spread of wild poliovirus. Geneva: WHO; 2014. [Accessed 20 Dec 2016]. Available from: http://www.who.int/mediacentre/news/statements/2014/polio-20140505/en/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Update on vaccine-derived polioviruses--worldwide, January 2008-June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(36):1002-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19763076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch MA. Ending Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame. N Engl J Med. 2018;379(9):801-3. 10.1056/NEJMp1808903</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1808903</ArticleId><ArticleId IdType="pmc">PMC8083018</ArticleId><ArticleId IdType="pubmed">30157390</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Regional Office for Europe (WHO/Europe). Report of the 32nd Meeting of the European Regional Certification Commission for Poliomyelitis Eradication. Copenhagen: WHO/Europe; 2018. Available from: http://www.euro.who.int/fr/health-topics/communicable-diseases/poliomyelitis/publications/2018/32nd-meeting-of-the-european-regional-commission-for-certification-of-poliomyelitis-eradication-rcc-report-2018</Citation></Reference><Reference><Citation>Ministerio de Sanidad y Consumo. Plan de actuaciones necesarias para la consecuci&#xf3;n del certificado de erradicaci&#xf3;n de la poliomielitis. [National Action Plan Aimed at the Achievement of the Certificate of Polio Eradication]. Madrid: Instituto de Salud Carlos III; 1998. Spanish. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/Plancertificadoerradicaionpolio.pdf</Citation></Reference><Reference><Citation>Centro Nacional de Epidemiolog&#xed;a. Plan de Acci&#xf3;n para mantener un estado libre de polio en Espa&#xf1;a, tras obtener el certificado de la interrupci&#xf3;n de la transmisi&#xf3;n de poliovirus salvaje en la Regi&#xf3;n Europea. [Action Plan to sustain polio-free status in Spain after elimination certification]. Madrid: Instituto de Salud Carlos III; 2007. Spanish. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/PLANESTADOLIBREPOLIO032007.pdf</Citation></Reference><Reference><Citation>Ministerio de Sanidad, Asuntos Sociales e Igualdad S. Plan de Acci&#xf3;n en Espa&#xf1;a para la Erradicaci&#xf3;n de la Poliomielitis. [Plan of action in Spain for the eradication of poliomyelitis]. Spain: Government of Spain; 2016. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/PlanPolio/docs/Plan_erradicacion_poliomielitis.pdf</Citation></Reference><Reference><Citation>World Health Organization (WHO). Polio Laboratory Manual, 4th edition. Geneva: WHO;2004. Available from: http://apps.who.int/iris/bitstream/10665/68762/1/WHO_IVB_04.10.pdf</Citation></Reference><Reference><Citation>World Health Organization (WHO). An alternative test algorithm for poliovirus isolation and characterization. Polio Laboratory Manual 4th edition. Geneva: WHO;2004: Available from: http://polioeradication.org/wp-content/uploads/2017/05/NewAlgorithmForPoliovirusIsolationSupplement1.pdf</Citation></Reference><Reference><Citation>Centro Nacional de Epidemiolog&#xed;a. Red Nacional de Vigilancia Epidemiol&#xf3;gica. Protocolos de enfermedades de declaraci&#xf3;n obligatoria. [National Guidelines for Notifiable Disease Reporting and Management]. Madrid: Instituto de Salud Carlos III;2013. Spanish. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/PROTOCOLOS_RENAVE.pdf</Citation></Reference><Reference><Citation>World Health Organization (WHO) Regional Office for Europe&#x200e;.&#xa0;Guidelines on responding to the detection of wild poliovirus in the WHO European Region.&#xa0;Copenhagen: WHO Regional Office for Europe; 2007. Available from: http://www.who.int/iris/handle/10665/107877</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). International classification of diseases, ninth revision, clinical modification (ICD-9-CM). Atlanta: CDC. [Accessed 3 May 2014]. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm</Citation></Reference><Reference><Citation>Avell&#xf3;n A, Cabrerizo M, de Miguel T, P&#xe9;rez-Bre&#xf1;a P, Tenorio A, P&#xe9;rez JL, et al. Paralysis case and contact spread of recombinant vaccine-derived poliovirus, Spain. Emerg Infect Dis. 2008;14(11):1807-9. 10.3201/eid1411.080517</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1411.080517</ArticleId><ArticleId IdType="pmc">PMC2630745</ArticleId><ArticleId IdType="pubmed">18976579</ArticleId></ArticleIdList></Reference><Reference><Citation>Centro Nacional de Epidemiolog&#xed;a, Instituto de Salud Carlos III (ISCIII). Resultados de la vigilancia de Par&#xe1;lisis Fl&#xe1;ccida Aguda en Espa&#xf1;a, 2002-2017. [Results of the surveillance of Acute Flaccid Paralysis in Spain, 2002-2017]. Madrid; 2018. Spanish. Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-enfermedades-prevenibles-vacunacion/sistema-vigilancia-paralisis-flacida-aguda.shtml</Citation></Reference><Reference><Citation>Trallero G, Avellon A, Otero A, De Miguel T, P&#xe9;rez C, Rabella N, et al. Enteroviruses in Spain over the decade 1998-2007: virological and epidemiological studies. J Clin Virol. 2010;47(2):170-6. 10.1016/j.jcv.2009.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.11.013</ArticleId><ArticleId IdType="pubmed">20007023</ArticleId></ArticleIdList></Reference><Reference><Citation>Trallero G, Cabrerizo M, Avell&#xf3;n A, Red de Laboratorios de Vigilancia de Par&#xe1;lisis Fl&#xe1;cida Aguda Papel del Laboratorio Nacional de Poliovirus en el Programa de erradicaci&#xf3;n y vigilancia de la poliomielitis. [Role of the National Poliovirus Laboratory for the Program of eradication and poliomyelitis surveillance]. Rev Esp Salud Publica. 2013;87(5):471-9. 10.4321/S1135-57272013000500006</Citation><ArticleIdList><ArticleId IdType="doi">10.4321/S1135-57272013000500006</ArticleId><ArticleId IdType="pubmed">24322284</ArticleId></ArticleIdList></Reference><Reference><Citation>Tello Anchuela O. Fase actual de control de la vigilancia epidemiol&#xf3;gica de la poliomielitis en Espa&#xf1;a. [Current phase of control of epidemiological surveillance of poliomyelitis in Spain]. Rev Esp Salud Publica. 2013;87(5):481-96. 10.4321/S1135-57272013000500007</Citation><ArticleIdList><ArticleId IdType="doi">10.4321/S1135-57272013000500007</ArticleId><ArticleId IdType="pubmed">24322285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovi T, Stenvik M. Surveillance of patients with acute flaccid paralysis in Finland: report of a pilot study. Bull World Health Organ. 2000;78(3):298-304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2560699</ArticleId><ArticleId IdType="pubmed">10812725</ArticleId></ArticleIdList></Reference><Reference><Citation>Suresh S, Forgie S, Robinson J. Non-polio Enterovirus detection with acute flaccid paralysis: A systematic review. J Med Virol. 2018;90(1):3-7. 10.1002/jmv.24933</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24933</ArticleId><ArticleId IdType="pubmed">28857219</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). Rapid Risk Assessment &#x2013;Enterovirus detections associated with severe neurological symptoms in children and adults in European countries, 8 August 2016. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/Publications/01-08-2016-RRA-Enterovirus%2071-Spain,%20France,%20Netherlands.pdf</Citation></Reference><Reference><Citation>Antona D, Kossorotoff M, Schuffenecker I, Mirand A, Leruez-Ville M, Bassi C, et al. Severe paediatric conditions linked with EV-A71 and EV-D68, France, May to October 2016. Euro Surveill. 2016;21(46):30402. 10.2807/1560-7917.ES.2016.21.46.30402</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.46.30402</ArticleId><ArticleId IdType="pmc">PMC5144948</ArticleId><ArticleId IdType="pubmed">27918268</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas-Alba D, de Sevilla MF, Valero-Rello A, Fortuny C, Garc&#xed;a-Garc&#xed;a JJ, Ortez C, et al. Outbreak of brainstem encephalitis associated with enterovirus-A71 in Catalonia, Spain (2016): a clinical observational study in a children&#x2019;s reference centre in Catalonia. Clin Microbiol Infect. 2017;23(11):874-81. 10.1016/j.cmi.2017.03.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2017.03.016</ArticleId><ArticleId IdType="pubmed">28344164</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrerizo M, Grupo Para El Estudio de Las Infecciones Por Enterovirus Y Parechovirus GPEELIPEYP. Importancia de los enterovirus en neuropediatria: de los poliovirus a otros enterovirus. [Importance of enteroviruses in neuropaediatrics: from polioviruses to other enteroviruses]. Rev Neurol. 2017;64(s03):S35-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28524217</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrerizo M, Garc&#xed;a-I&#xf1;iguez JP, Munell F, Amado A, Madurga-Revilla P, Rodrigo C, et al. First cases of severe flaccid paralysis associated with enterovirus D68 infection in Spain, 2015-2016. Pediatr Infect Dis J. 2017;36(12):1214-6. 10.1097/INF.0000000000001668</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001668</ArticleId><ArticleId IdType="pubmed">28661963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang M, Mirand A, Savy N, Henquell C, Maridet S, Perignon R, et al. Acute flaccid paralysis following enterovirus D68 associated pneumonia, France, 2014. Euro Surveill. 2014;19(44):20952. 10.2807/1560-7917.ES2014.19.44.20952</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2014.19.44.20952</ArticleId><ArticleId IdType="pubmed">25394254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pariani E, Pellegrinelli L, Merlone AD, Piralla A, Baldanti F, Binda S. Letter to the editor: Need for a European network for enterovirus D68 surveillance after detections of EV-D68 of the new B3 lineage in Sweden and Italy, 2016. Euro Surveill. 2017;22(2):30440. 10.2807/1560-7917.ES.2017.22.2.30440</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.2.30440</ArticleId><ArticleId IdType="pmc">PMC5404488</ArticleId><ArticleId IdType="pubmed">28106530</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil M, Shulman LM, Heiman S, Stauber T, Alfandari J, Weiss L, et al. Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016. Euro Surveill. 2016;21(47):30408. 10.2807/1560-7917.ES.2016.21.47.30408</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2016.21.47.30408</ArticleId><ArticleId IdType="pmc">PMC5291147</ArticleId><ArticleId IdType="pubmed">27918258</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Seventieth World Health Assembly A70/14 Provisional Agenda item 12.3. Poliomyelitis. Geneva: WHO; 2017. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA70/A70_14-en.pdf</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>